SCHEMBL3546337

SCHEMBL3546337

Cc1ccc(-c2oncc2C(=O)N2CCC(O)(c3ccccc3)CC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP46A1 Q9Y6A2 1/20 0.56
HCRTR1 O43613 2/20 0.47
HCRTR2 O43614 2/20 0.47
SCD5 Q86SK9 1/20 0.46
ALDH1A1 P00352 6/20 0.46
LMNA P02545 2/20 0.46
POLB P06746 2/20 0.45
PKM P14618 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.43
OPRM1 P35372 3/20 0.43
OPRK1 P41145 3/20 0.43
OPRL1 P41146 3/20 0.43
OPRD1 P41143 2/20 0.43
SPR P35270 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3550743 0.94 CYP46A1 (0.49) CYP46A1HCRTR1HCRTR2SCD5ALDH1A1
SCHEMBL3549477 0.89 ALDH1A1 (0.48) CYP46A1HCRTR1HCRTR2ALDH1A1SMN1; SMN2
SCHEMBL14304942 0.88 HCRTR1 (0.46) CYP46A1HCRTR1HCRTR2SCD5ALDH1A1
SCHEMBL3545194 0.85 F11 (0.50) HCRTR1HCRTR2ALDH1A1SPRCA12
SCHEMBL3542108 0.84 CYP46A1 (0.58) CYP46A1HCRTR1HCRTR2
SCHEMBL3543764 0.83 PROKR1 (0.42) CYP46A1HCRTR1HCRTR2ALDH1A1LMNA
SCHEMBL3543746 0.83 OPRM1 (0.53) LMNAOPRM1OPRK1OPRD1MEN1
SCHEMBL3545756 0.83 HCRTR1 (0.43) CYP46A1HCRTR1HCRTR2ALDH1A1LMNA
SCHEMBL3186687 0.81 ALDH1A1 (0.54) HCRTR1HCRTR2ALDH1A1LMNAPOLB
SCHEMBL3548124 0.81 MEN1 (0.53) HCRTR1HCRTR2SCD5ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7666888-B2 Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 AMGEN INC. (US) 2010-02-23 US disclosed
US-7666888-B2 Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 AMGEN INC. (US) 2010-02-23 US disclosed
US-7666888-B2 Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 AMGEN INC. (US) 2010-02-23 US disclosed
EP-2051977-A2 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1 Amgen Inc. (US) 2009-04-29 EP disclosed
WO-2008011453-A2 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 AMGEN INC. (US) 2008-01-24 WO disclosed
WO-2008011453-A2 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 AMGEN INC. (US) 2008-01-24 WO disclosed
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 AMGEN INC. 2008-01-24 US disclosed
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 AMGEN INC. 2008-01-24 US disclosed
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 AMGEN INC. 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 HSD17B1, HSD11B1, HSD17B11 CYP46A1 30/4885HCRTR1 314/4885HCRTR2 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.